Skip to main content
. 2022 Jul 21;12:12491. doi: 10.1038/s41598-022-16776-1

Figure 6.

Figure 6

The 29F.1A12 anti-PD-1 monoclonal antibody blocks PD-1 interactions with recombinant PD-L1 on live B16-F10 melanoma cells. (a,b) Representative histograms (left) and % recombinant (r)PD-L1 binding (mean ± s.e.m., right), to live (FVD−) (a) B16-F10 wild-type (WT) or PD-1-overexpressing (OE) melanoma cells or (b) PD-1+ (red line) versus PD-1− (black line), RMP1-30-gated B16-F10 WT melanoma cell subset. (c) Relative Pdcd1 expression (mean ± s.d., two distinct primer sets), as determined by real-time qPCR, in live (FVD−) FACS-sorted, rPD-L1+/− B16-F10 WT subpopulations. (d) Effect of antibody-mediated PD-1 blockade (29F.1A12, black dashed line) versus isotype control (red line) on rPD-L1 binding to B16-F10 WT or PD-1 OE melanoma cells. Shown are representative histogram plots (left) and % rPD-L1 relative to isotype control (mean ± s.e.m., right). Results are representative of at least n = 3 independent experiments. *p < 0.01; ***p < 0.001.